Johnson & Johnson


Market Cap$350.05B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Johnson & JohnsonJohnson & Johnson9.13.27%55%4.50.5

Earnings Call Q4 2023

January 23, 2024 - AI Summary

Johnson & Johnson reported strong financial results for Q4 2023, with worldwide sales of $21.4 billion, representing a 7.2% increase compared to the previous year.
The company's Innovative Medicine business delivered above-market operational sales growth of 9.5%, excluding the COVID-19 vaccine, driven by key brands and new product launches.
MedTech also performed well, with operational sales growth of 9.1%, reaching over $30 billion in sales for the first time.

Exclusive for Stockcircle Pro members

Sign upSign Up

Target Price by Analysts

17.2% upsideJohnson & Johnson Target Price DetailsTarget Price

Current Fair Value

5.7% upside

Undervalued by 5.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$350.05 Billion
Enterprise Value$357.47 Billion
Dividend Yield$4.7543 (3.27%)
Earnings per Share$15.29
Outstanding Shares2,406,679,183
Avg 30 Day Volume7,500,622


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio9.1
Price to Sales4.48
Price to Book Ratio5.1
Enterprise Value to Revenue4.37
Enterprise Value to EBIT16.68
Enterprise Value to Net Income9
Total Debt to Enterprise0.09
Debt to Equity0.48

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Johnson & Johnson

CEO: Alex Gorsky

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today...